# Postoperative Adjuvant Therapy for CT041 Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma Patients

> **NCT06857786** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Peking University** · enrollment: 48 (estimated)

## Conditions studied

- Gastroesophageal Junction Adenocarcinoma
- Gastric Adenocarcinoma

## Interventions

- **DRUG:** Drug: CT041 autologous CAR T-cell injection

## Key facts

- **NCT ID:** NCT06857786
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03-10
- **Primary completion:** 2027-06-30
- **Final completion:** 2030-06-30
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06857786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06857786, "Postoperative Adjuvant Therapy for CT041 Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06857786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*